BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1428 related articles for article (PubMed ID: 22217193)

  • 1. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control.
    Akalin S; Berntorp K; Ceriello A; Das AK; Kilpatrick ES; Koblik T; Munichoodappa CS; Pan CY; Rosenthall W; Shestakova M; Wolnik B; Woo V; Yang WY; Yilmaz MT;
    Int J Clin Pract; 2009 Oct; 63(10):1421-5. PubMed ID: 19769698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes.
    Weiss IA; Valiquette G; Schwarcz MD
    Cardiol Rev; 2009; 17(4):165-75. PubMed ID: 19525678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials.
    Bangalore S; Kumar S; Lobach I; Messerli FH
    Circulation; 2011 Jun; 123(24):2799-810, 9 p following 810. PubMed ID: 21632497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
    Betteridge J
    Am J Med; 2005 Dec; 118 Suppl 12A():10-5. PubMed ID: 16356802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycemic targets for patients with type 2 diabetes mellitus.
    Hamnvik OP; McMahon GT
    Mt Sinai J Med; 2009 Jun; 76(3):227-33. PubMed ID: 19421966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in reducing the burden of vascular disease in type 2 diabetes.
    Chalmers J; Joshi R; Patel A
    Clin Exp Pharmacol Physiol; 2008 Apr; 35(4):434-7. PubMed ID: 18307736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH
    Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive statin therapy for Indians: Part-I. Benefits.
    Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
    Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trials of cardiovascular risk factor management in type 2 diabetes.
    Patel A; Joshi R; de Galan B
    Curr Opin Cardiol; 2009 Jul; 24(4):288-94. PubMed ID: 19322080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A
    Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials.
    Tkác I
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S57-62. PubMed ID: 20115934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADVANCE: action in diabetes and vascular disease.
    Patel A; Chalmers J; Poulter N
    J Hum Hypertens; 2005 Jun; 19 Suppl 1():S27-32. PubMed ID: 16075030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatment guidelines for a patient with diabetes and hypertension.
    Mogensen CE
    J Hypertens Suppl; 2003 Mar; 21(1):S25-30. PubMed ID: 12769164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of new diabetes treatment trials: should current clinical practice be altered?
    Kravetz JD; Federman DG
    Postgrad Med; 2009 May; 121(3):67-72. PubMed ID: 19491542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperlipidaemia and cardiovascular disease: do fibrates have a role?
    Saha SA; Arora RR
    Curr Opin Lipidol; 2011 Aug; 22(4):270-6. PubMed ID: 21519250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CARDS on the table: should everybody with type 2 diabetes take a statin?
    Lee JD; Morrissey JR; Mikhailidis DP; Patel V
    Curr Med Res Opin; 2005 Mar; 21(3):357-62. PubMed ID: 15811203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.